Our order intake decreased substantially by 27% from an extraordinary high level of last year, where we booked a much higher volume of large orders in Energy and Transportation & Logistics, including the, if you remember, the EUR 3.7 billion ICx order in Germany. Therefore, our book-to-bill decreased to 0.91, but we expect to see a rebound to above 1 in the fourth quarter. Our backlog remains at EUR 100 billion, supported by translation effects of the weakening euro.We achieved moderate revenue growth of 3%, driven by continued backlog conversion in Energy and impressive competitive strength in our Healthcare sector. Profitability clearly exceeded the prior year level, which was substantially burdened by the Areva arbitration decision and the particle therapy reevaluation. Fossil and DX delivered strong earnings, however, profitability was impacted by higher OpEx in all sectors and significantly lower contribution from the industrial sector.
Siemens AG Management Discusses Q3 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts